JP2009524677A - 炎症および免疫関連使用用のチアゾールおよびチアジアゾール化合物 - Google Patents

炎症および免疫関連使用用のチアゾールおよびチアジアゾール化合物 Download PDF

Info

Publication number
JP2009524677A
JP2009524677A JP2008552423A JP2008552423A JP2009524677A JP 2009524677 A JP2009524677 A JP 2009524677A JP 2008552423 A JP2008552423 A JP 2008552423A JP 2008552423 A JP2008552423 A JP 2008552423A JP 2009524677 A JP2009524677 A JP 2009524677A
Authority
JP
Japan
Prior art keywords
optionally substituted
phenyl
compound
thiazol
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008552423A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009524677A5 (enExample
Inventor
フウ ボ，ニャ
チェン，ショウジュン
チェ，クィンリン
シェ，ユー
Original Assignee
シンタ ファーマシューティカルズ コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シンタ ファーマシューティカルズ コーポレーション filed Critical シンタ ファーマシューティカルズ コーポレーション
Publication of JP2009524677A publication Critical patent/JP2009524677A/ja
Publication of JP2009524677A5 publication Critical patent/JP2009524677A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
JP2008552423A 2006-01-25 2007-01-25 炎症および免疫関連使用用のチアゾールおよびチアジアゾール化合物 Pending JP2009524677A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76197406P 2006-01-25 2006-01-25
US76193306P 2006-01-25 2006-01-25
PCT/US2007/002121 WO2007087427A2 (en) 2006-01-25 2007-01-25 Thiazole and thiadiazole compounds for inflammation and immune-related uses

Publications (2)

Publication Number Publication Date
JP2009524677A true JP2009524677A (ja) 2009-07-02
JP2009524677A5 JP2009524677A5 (enExample) 2010-03-11

Family

ID=38309864

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008552423A Pending JP2009524677A (ja) 2006-01-25 2007-01-25 炎症および免疫関連使用用のチアゾールおよびチアジアゾール化合物

Country Status (7)

Country Link
US (2) US8455658B2 (enExample)
EP (1) EP1983980A4 (enExample)
JP (1) JP2009524677A (enExample)
AU (1) AU2007208225B2 (enExample)
CA (1) CA2639910A1 (enExample)
TW (1) TWI444370B (enExample)
WO (1) WO2007087427A2 (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013530240A (ja) * 2010-07-02 2013-07-25 ギリアード サイエンシーズ， インコーポレイテッド アポトーシスシグナル調節キナーゼ阻害剤
JP2013536259A (ja) * 2010-08-27 2013-09-19 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
WO2013146754A1 (ja) * 2012-03-27 2013-10-03 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素５員環誘導体
JP2015107948A (ja) * 2013-12-06 2015-06-11 住友精化株式会社 芳香族チアゾール化合物の製造方法
JP2015521193A (ja) * 2012-05-31 2015-07-27 フェネックス ファーマシューティカルス アーゲー オーファン核内受容体ＲＯＲγの調整剤としてのカルボキサミドまたはスルホンアミド置換されたチアゾールおよび関連する誘導体
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
JP2019501168A (ja) * 2015-12-21 2019-01-17 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ 新規の１，２，３−トリアゾール−チアゾール化合物とその調製方法と利用
WO2021132422A1 (ja) * 2019-12-25 2021-07-01 アステラス製薬株式会社 ピリダジニルチアアゾールカルボキシアミド化合物
JPWO2022114164A1 (enExample) * 2020-11-30 2022-06-02

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003201573B2 (en) * 2002-01-22 2009-02-26 Biomatera Inc. Method of drying biodegradable polymers
CA2640091A1 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Vinyl-phenyl derivatives for inflammation and immune-related uses
CA2639913A1 (en) * 2006-01-25 2007-08-02 Synta Pharmaceutical Corp. Phenyl and pyridyl compounds for inflammation and immune-related uses
WO2007087442A2 (en) * 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Substituted biaryl compounds for inflammation and immune-related uses
CA2640090A1 (en) * 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Substituted aromatic compounds for inflammation and immune-related uses
AU2007227210A1 (en) 2006-03-20 2007-09-27 Synta Pharmaceuticals Corp. Benzoimidazolyl-parazine compounds for inflammation and immune-related uses
US8779154B2 (en) * 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
CA2696349A1 (en) 2007-08-15 2009-02-19 President And Fellows Of Harvard College Heterocyclic inhibitors of necroptosis
JP5411141B2 (ja) * 2007-09-10 2014-02-12 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
US8389567B2 (en) * 2007-12-12 2013-03-05 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2240029A4 (en) * 2008-01-07 2012-08-22 Synta Pharmaceuticals Corp COMPOUNDS FOR USE AGAINST INFLAMMATORY AND IMMUNOMIC DISEASES
CA2734500A1 (en) * 2008-08-27 2010-03-11 Calcimedica Inc. Compounds that modulate intracellular calcium
US8524763B2 (en) * 2008-09-22 2013-09-03 Calcimedica, Inc. Inhibitors of store operated calcium release
BRPI0919004A2 (pt) 2008-09-22 2019-09-24 Cayman Chem Co composto de multiheteroarila como inibidores de h-pgds e sua utilização para o tratamento de doenças mediadas por prostaglandina d2
US8143269B2 (en) * 2008-10-03 2012-03-27 Calcimedica, Inc. Inhibitors of store operated calcium release
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
US8618307B2 (en) * 2009-09-16 2013-12-31 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2305660A1 (en) * 2009-09-25 2011-04-06 Almirall, S.A. New thiadiazole derivatives
US8377970B2 (en) 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
HUE029570T2 (en) 2010-04-27 2017-03-28 Calcimedica Inc Intracellular calcium modifying compounds
US10703722B2 (en) 2010-04-27 2020-07-07 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2563759B1 (en) 2010-04-27 2022-04-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
RU2012154447A (ru) 2010-05-12 2014-06-20 Вандербилт Юниверсити Гетероциклические сульфоновые аллостерические потенциаторы mglur4, композиции и способы лечения неврологических дисфункций
US8815271B2 (en) 2010-11-03 2014-08-26 Dow Agrosciences, Llc. Pesticidal compositions and processes related thereto
CN102532123B (zh) * 2010-12-29 2016-03-09 中国医学科学院药物研究所 噻唑-5-甲酰胺化合物、及其制法和药物组合物与用途
UA112539C2 (uk) * 2011-03-03 2016-09-26 Новартіс Аг Спосіб одержання похідних 2-карбоксамідциклоаміносечовини
US9255072B2 (en) * 2011-03-04 2016-02-09 National Health Rsearch Institutes Pyrazole compounds and thiazole compounds as protein kinases inhibitors
WO2012121168A1 (ja) * 2011-03-04 2012-09-13 国立大学法人京都大学 キナーゼ阻害剤
EP2704701B1 (en) 2011-05-03 2018-01-03 PRCL Research Inc. Compounds for inflammation and immune-related uses
US20120316182A1 (en) 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
CN103058949A (zh) * 2011-10-18 2013-04-24 华东理工大学 做为dhodh抑制剂的噻唑衍生物及其应用
US9856240B2 (en) 2011-10-19 2018-01-02 Calcimedica, Inc. Compounds that modulate intracellular calcium
US8937083B2 (en) 2011-10-26 2015-01-20 DowAgroSciences, LLC Pesticidal compositions and processes related thereto
RU2627654C2 (ru) 2012-04-27 2017-08-09 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Пестицидные композиции и относящиеся к ним способы
US9708288B2 (en) 2012-04-27 2017-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
US9282739B2 (en) 2012-04-27 2016-03-15 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
EP2746260A1 (en) 2012-12-21 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
EP2746259A1 (en) 2012-12-21 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
EP2943196A1 (en) 2013-01-10 2015-11-18 Grünenthal GmbH Pyrazolyl-based carboxamides i as crac channel inhibitors
EP2943197A1 (en) 2013-01-10 2015-11-18 Grünenthal GmbH Pyrazolyl-based carboxamides ii as crac channel inhibitors
EP2968276A4 (en) 2013-03-15 2017-02-15 President and Fellows of Harvard College Hybrid necroptosis inhibitors
ES2634628T3 (es) 2013-07-02 2017-09-28 Bristol-Myers Squibb Company Derivados tricíclicos de pirido-carboxamida como inhibidores ROCK
EP3016951B1 (en) 2013-07-02 2017-05-31 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
EP2848615A1 (en) 2013-07-03 2015-03-18 Almirall, S.A. New pyrazole derivatives as CRAC channel modulators
CN105636440A (zh) 2013-10-17 2016-06-01 美国陶氏益农公司 制备杀虫化合物的方法
JP2016535010A (ja) 2013-10-17 2016-11-10 ダウ アグロサイエンシィズ エルエルシー 有害生物防除性化合物の製造方法
CN105636446B (zh) 2013-10-17 2018-07-13 美国陶氏益农公司 制备杀虫化合物的方法
KR20160075565A (ko) 2013-10-17 2016-06-29 다우 아그로사이언시즈 엘엘씨 살충성 화합물의 제조 방법
EP3057426A4 (en) 2013-10-17 2017-03-29 Dow AgroSciences LLC Processes for the preparation of pesticidal compounds
BR112016008070B8 (pt) 2013-10-17 2022-08-23 Dow Agrosciences Llc Compostos pesticidas, e seus processos de preparação
EP3057430A4 (en) 2013-10-17 2017-09-13 Dow AgroSciences LLC Processes for the preparation of pesticidal compounds
AR098091A1 (es) 2013-10-22 2016-05-04 Dow Agrosciences Llc Composiciones pesticidas sinérgicas y métodos relacionados
CA2927206A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
CA2927226A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
EP3060044A4 (en) 2013-10-22 2017-04-05 Dow AgroSciences LLC Synergistic pesticidal compositions and related methods
WO2015061140A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
CN105792650A (zh) 2013-10-22 2016-07-20 美国陶氏益农公司 协同杀虫组合物和相关方法
US9155304B2 (en) 2013-10-22 2015-10-13 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
RU2658995C2 (ru) 2013-10-22 2018-06-26 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Пестицидные композиции и связанные с ними способы
JP2016538265A (ja) 2013-10-22 2016-12-08 ダウ アグロサイエンシィズ エルエルシー 相乗的有害生物防除組成物および関連する方法
US9497966B2 (en) 2013-10-22 2016-11-22 Dow Agrosciences Llc Pesticidal compositions and related methods
CN105792652A (zh) 2013-10-22 2016-07-20 美国陶氏益农公司 协同杀虫组合物和相关方法
CN105828608A (zh) 2013-10-22 2016-08-03 美国陶氏益农公司 杀虫组合物和与其相关的方法
MX2016005319A (es) 2013-10-22 2016-08-12 Dow Agrosciences Llc Composiciones pesticidas y metodos relacionados.
AR098101A1 (es) 2013-10-22 2016-05-04 Dow Agrosciences Llc Composiciones plaguicidas y métodos relacionados
AR098094A1 (es) 2013-10-22 2016-05-04 Dow Agrosciences Llc Composiciones plaguicidas sinérgicas y métodos relacionados
EP3060054A4 (en) 2013-10-22 2017-04-05 Dow AgroSciences LLC Synergistic pesticidal compositions and related methods
US9137998B2 (en) 2013-10-22 2015-09-22 Dow Agrosciences Llc Pesticidal compositions and related methods
WO2015197187A1 (en) 2014-06-24 2015-12-30 Grünenthal GmbH Pyrazolyl-based carboxamides v
EP3174856A4 (en) 2014-07-31 2018-01-10 Dow AgroSciences LLC Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
EP3186229A4 (en) 2014-07-31 2018-01-10 Dow AgroSciences LLC Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
US9249122B1 (en) 2014-07-31 2016-02-02 Dow Agrosciences Llc Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine
WO2016028328A1 (en) 2014-08-19 2016-02-25 Dow Agrosciences Llc Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
JP2017528469A (ja) 2014-09-12 2017-09-28 ダウ アグロサイエンシィズ エルエルシー ３−（３−クロロ−１ｈ−ピラゾール−１−イル）ピリジンの調製方法
EP3212642B1 (en) 2014-10-30 2019-10-30 Janssen Pharmaceutica NV Amide substituted thiazoles as modulators of rorgammat
LT3212641T (lt) 2014-10-30 2019-02-11 Janssen Pharmaceutica Nv Tiazolai, kaip roryt moduliatoriai
TWI667230B (zh) 2014-10-30 2019-08-01 比利時商健生藥品公司 用作ＲＯＲγｔ調節劑之三氟甲基醇
CN114712513B (zh) 2015-02-27 2026-02-10 钙医学公司 胰腺炎治疗
WO2016183173A1 (en) * 2015-05-12 2016-11-17 Avista Pharma Solutions Antiparasitic compounds
AU2016306301B2 (en) 2015-08-07 2021-02-11 Calcimedica, Inc. Use of CRAC channel inhibitors for the treatment of stroke and traumatic brain injury
KR101857714B1 (ko) * 2016-02-05 2018-05-15 연세대학교 산학협력단 신규 아미드 화합물 및 이의 용도
PT3442580T (pt) 2016-04-11 2020-12-23 Genfit Métodos de tratamento para doenças colestáticas e fibróticas
JP2019513762A (ja) * 2016-04-11 2019-05-30 ジェンフィＧｅｎｆｉｔ 胆汁うっ滞及び線維症の処置方法
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑
CN105943535B (zh) * 2016-05-23 2017-05-31 泉州市景江电子科技有限公司 一种治疗乙肝的药物组合物
US10100033B2 (en) 2016-12-29 2018-10-16 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
WO2018125817A1 (en) 2016-12-29 2018-07-05 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
CN107400124A (zh) * 2017-09-14 2017-11-28 刘双伟 一种烟酰胺类化合物、合成路线及其在制备抗过敏药物中的应用
CN108299418A (zh) * 2017-09-14 2018-07-20 刘双伟 一种抗过敏和哮喘的噻唑基烟酰胺类化合物的合成方法
EP3806958B1 (en) 2018-06-18 2022-09-07 Janssen Pharmaceutica NV 6-aminopyridin-3-yl pyrazoles as modulators of roryt
CA3103929A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Phenyl substituted pyrazoles as modulators of roryt
CN112334450A (zh) 2018-06-18 2021-02-05 詹森药业有限公司 作为RORγt的调节剂的苯基和吡啶基取代的咪唑
ES2925473T3 (es) 2018-06-18 2022-10-18 Janssen Pharmaceutica Nv Pirazoles de piridinilo como moduladores de RORyt
CN113557020A (zh) 2018-09-14 2021-10-26 瑞真药业公司 包含crac抑制剂和皮质类固醇的组合物及其使用方法
KR102732033B1 (ko) * 2019-07-26 2024-11-20 아주대학교산학협력단 Tlr7 및 tlr9의 신호전달 경로를 억제하는 신규한 소분자 화합물 및 그 용도
CA3167339A1 (en) 2020-01-13 2021-07-22 Verge Analytics, Inc. Substituted pyrazolo-pyrimidines and uses thereof
US12544371B2 (en) 2020-03-20 2026-02-10 Calcimedica, Inc. Methods and compositions for treating acute lung injury and acute respiratory distress syndrome
US12522589B2 (en) 2020-11-13 2026-01-13 Calcimedica, Inc. Synthesis of CRAC channel inhibitors
CN116199682B (zh) * 2023-03-17 2025-04-22 凯思凯迪（上海）医药科技有限公司 一种苯基噻唑基苯甲酰胺类化合物及其应用
KR20250144817A (ko) * 2024-03-27 2025-10-13 동국대학교 산학협력단 신규 옥사다이아졸 유도체 및 이를 포함하는 암 예방 또는 치료용 조성물
CN118415982B (zh) * 2024-04-15 2024-12-10 山东京卫制药有限公司 一种硝酸2-（4-甲基噻唑-5-基）乙酯盐酸盐鼻喷剂及其制备方法

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52105173A (en) * 1976-02-09 1977-09-03 Lilly Co Eli Preparation and use of thiadiazolylbenzamides
JPH0228175A (ja) * 1987-12-14 1990-01-30 Sawai Seiyaku Kk チアゾール環およびテトラゾール環を有するカルボキシアミド誘導体およびその用途
WO1995007278A1 (en) * 1993-09-09 1995-03-16 E.I. Du Pont De Nemours And Company Fungicidal, miticidal and arthropodicidal aminopyrimidines
WO2002049632A1 (en) * 2000-12-18 2002-06-27 Institute Of Medicinal Molecular Design. Inc. Inhibitors against the production and release of inflammatory cytokines
JP2002521408A (ja) * 1998-07-28 2002-07-16 スミスクライン・ビーチャム・コーポレイション 化合物および方法
JP2002302445A (ja) * 2001-02-02 2002-10-18 Takeda Chem Ind Ltd Ｊｎｋ阻害剤
JP2002302488A (ja) * 2000-03-30 2002-10-18 Takeda Chem Ind Ltd 置換１，３−チアゾール化合物、その製造法および用途
JP2002302458A (ja) * 2000-12-26 2002-10-18 Takeda Chem Ind Ltd 併用薬
EP1512396A1 (en) * 2002-06-05 2005-03-09 Institute of Medicinal Molecular Design, Inc. Inhibitors against the activation of ap-1 and nfat
US20050107438A1 (en) * 2003-09-03 2005-05-19 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising 3-[(2-{[4-(Hexyloxycarbonylaminoiminomethyl) phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester or a salt therefore
US20050176789A1 (en) * 2003-09-06 2005-08-11 Hadida Ruah Sara S. Modulators of ATP-Binding Cassette transporters
US20050272699A1 (en) * 2004-03-25 2005-12-08 Shoujun Chen Acrylonitrile derivatives for inflammation and immune-related uses
WO2006125803A1 (en) * 2005-05-24 2006-11-30 Laboratoires Serono S.A. Thiazole derivatives and use thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3794636A (en) * 1971-09-03 1974-02-26 Uniroyal Ltd Process for preparation of thiazole hydrohalides
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4141984A (en) 1976-11-10 1979-02-27 Eli Lilly And Company N-(1,3,4-thiadiazol-2-yl)benzamides
DD138903A1 (de) * 1978-08-25 1979-11-28 Hans U Kibbel Verfahren zur herstellung von 4-alkylmercapto-2-aryl-5-aryliden-imino-thiazolen
DD222022A1 (de) * 1984-02-27 1985-05-08 Pieck Uni Rostock W Verfahren zur herstellung von alkylammonium 2-aryl-5-benzyliden-aminothiazol-4-thiolaten
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
DE3864248D1 (de) * 1987-12-14 1991-09-19 Sawai Seiyaku Kk Carboxamide mit tetrazol- und thiazol-ringen und ihre anwendung.
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5244867A (en) * 1989-09-26 1993-09-14 Basf Aktiengesellschaft Oxazole- and thiazolecarboxamides
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
FR2677356B1 (fr) 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
JPH07149746A (ja) 1993-11-30 1995-06-13 Hisamitsu Pharmaceut Co Inc 新規な２−置換アミノチアゾール誘導体
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
WO1996003392A1 (en) 1994-07-27 1996-02-08 G.D. Searle & Co. Substituted thiazoles for the treatment of inflammation
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
MY128323A (en) 1996-09-30 2007-01-31 Otsuka Pharma Co Ltd Thiazole derivatives for inhibition of cytokine production and of cell adhesion
AU3126700A (en) 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
CA2380206A1 (en) 1999-07-26 2001-02-01 Shionogi & Co., Ltd. Pharmaceutical compositions exhibiting thrombopoietin receptor agonism
EP1268474A2 (en) 2000-03-30 2003-01-02 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
JP4880816B2 (ja) 2000-12-15 2012-02-22 株式会社ヤクルト本社 皮膚老化防止剤
EP1354603A1 (en) * 2000-12-26 2003-10-22 Takeda Chemical Industries, Ltd. Concomitant drugs
EP1364949A4 (en) * 2001-02-02 2005-11-23 Takeda Pharmaceutical JNK INHIBITOR
WO2003015717A2 (en) 2001-08-17 2003-02-27 Merck & Co., Inc. Tyrosine kinase inhibitors
DE60324898D1 (de) * 2002-02-25 2009-01-08 Lilly Co Eli Modulatoren von peroxisome proliferator-aktivierten rezeptoren
US20040110802A1 (en) 2002-08-23 2004-06-10 Atli Thorarensen Antibacterial benzoic acid derivatives
US6737382B1 (en) 2002-10-23 2004-05-18 Nippon Soda Co. Ltd. Insecticidal aminothiazole derivatives
EP1559422B1 (en) 2002-11-08 2014-04-30 Takeda Pharmaceutical Company Limited Receptor function controlling agent
US7273866B2 (en) 2002-12-20 2007-09-25 Bristol-Myers Squibb Company 2-aryl thiazole derivatives as KCNQ modulators
US6987118B2 (en) * 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
WO2005002673A1 (en) 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
KR20060054308A (ko) 2003-07-16 2006-05-22 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 피부 색소침착의 치료제
EP1653968A4 (en) 2003-07-23 2006-09-06 Synta Pharmaceuticals Corp METHOD FOR MODULATING CALCIUMION RELIEF ACTIVATED CALCIUMION CHANNELS
PT1671635E (pt) * 2003-10-08 2012-01-17 Meiji Seika Pharma Co Ltd Composição de antibiótico amorfo contendo cefditoreno pivoxil
WO2005044194A2 (en) 2003-10-28 2005-05-19 Pharmacia Corporation TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR
JP4638355B2 (ja) * 2003-12-26 2011-02-23 協和発酵キリン株式会社 チアゾール誘導体
US7902356B2 (en) 2004-12-17 2011-03-08 Eli Lilly And Company Thiazolopyridinone derivates as MCH receptor antagonists
CA2640090A1 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Substituted aromatic compounds for inflammation and immune-related uses
CA2639913A1 (en) 2006-01-25 2007-08-02 Synta Pharmaceutical Corp. Phenyl and pyridyl compounds for inflammation and immune-related uses
CA2640091A1 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Vinyl-phenyl derivatives for inflammation and immune-related uses
WO2007087442A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Substituted biaryl compounds for inflammation and immune-related uses

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52105173A (en) * 1976-02-09 1977-09-03 Lilly Co Eli Preparation and use of thiadiazolylbenzamides
JPH0228175A (ja) * 1987-12-14 1990-01-30 Sawai Seiyaku Kk チアゾール環およびテトラゾール環を有するカルボキシアミド誘導体およびその用途
WO1995007278A1 (en) * 1993-09-09 1995-03-16 E.I. Du Pont De Nemours And Company Fungicidal, miticidal and arthropodicidal aminopyrimidines
JP2002521408A (ja) * 1998-07-28 2002-07-16 スミスクライン・ビーチャム・コーポレイション 化合物および方法
JP2002302488A (ja) * 2000-03-30 2002-10-18 Takeda Chem Ind Ltd 置換１，３−チアゾール化合物、その製造法および用途
WO2002049632A1 (en) * 2000-12-18 2002-06-27 Institute Of Medicinal Molecular Design. Inc. Inhibitors against the production and release of inflammatory cytokines
JP2002302458A (ja) * 2000-12-26 2002-10-18 Takeda Chem Ind Ltd 併用薬
JP2002302445A (ja) * 2001-02-02 2002-10-18 Takeda Chem Ind Ltd Ｊｎｋ阻害剤
EP1512396A1 (en) * 2002-06-05 2005-03-09 Institute of Medicinal Molecular Design, Inc. Inhibitors against the activation of ap-1 and nfat
US20050107438A1 (en) * 2003-09-03 2005-05-19 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising 3-[(2-{[4-(Hexyloxycarbonylaminoiminomethyl) phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester or a salt therefore
US20050176789A1 (en) * 2003-09-06 2005-08-11 Hadida Ruah Sara S. Modulators of ATP-Binding Cassette transporters
US20050272699A1 (en) * 2004-03-25 2005-12-08 Shoujun Chen Acrylonitrile derivatives for inflammation and immune-related uses
WO2006125803A1 (en) * 2005-05-24 2006-11-30 Laboratoires Serono S.A. Thiazole derivatives and use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6012041329; Ｎａｔｕｒｗｉｓｓｅｎｓｃｈａｆｔｌｉｃｈｅ　Ｒｅｉｈｅ ３３, 1984, ４３-４８ *
JPN6012041331; Ｃｈｅｍ．　Ｌｅｔｔ． , 1985, １１１５-１１１６ *
JPN6012041333; Ｒｅｖｕｅ　Ｒｏｕｍａｉｎｅ　ｄｅ　Ｃｈｉｍｉｅ １８, 1973, ６８５-６９４ *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013530240A (ja) * 2010-07-02 2013-07-25 ギリアード サイエンシーズ， インコーポレイテッド アポトーシスシグナル調節キナーゼ阻害剤
JP2013536259A (ja) * 2010-08-27 2013-09-19 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
WO2013146754A1 (ja) * 2012-03-27 2013-10-03 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素５員環誘導体
JPWO2013146754A1 (ja) * 2012-03-27 2015-12-14 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素５員環誘導体
US9499533B2 (en) 2012-03-27 2016-11-22 Shionogi & Co., Ltd. Aromatic 5-membered heterocyclic derivative having TRPV4-Inhibiting activity
JP2015521193A (ja) * 2012-05-31 2015-07-27 フェネックス ファーマシューティカルス アーゲー オーファン核内受容体ＲＯＲγの調整剤としてのカルボキサミドまたはスルホンアミド置換されたチアゾールおよび関連する誘導体
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
JP2015107948A (ja) * 2013-12-06 2015-06-11 住友精化株式会社 芳香族チアゾール化合物の製造方法
JP2019501168A (ja) * 2015-12-21 2019-01-17 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ 新規の１，２，３−トリアゾール−チアゾール化合物とその調製方法と利用
CN113365994A (zh) * 2019-12-25 2021-09-07 安斯泰来制药株式会社 哒嗪基噻唑甲酰胺类化合物
WO2021132422A1 (ja) * 2019-12-25 2021-07-01 アステラス製薬株式会社 ピリダジニルチアアゾールカルボキシアミド化合物
JP6948659B1 (ja) * 2019-12-25 2021-10-13 アステラス製薬株式会社 ピリダジニルチアアゾールカルボキシアミド化合物
US12227517B2 (en) 2019-12-25 2025-02-18 Astellas Pharma Inc. Pyridazinyl-thiazolecarboxamide compound
AU2020413997B2 (en) * 2019-12-25 2026-01-08 Astellas Pharma Inc. Pyridazinyl-thiazolecarboxamide compound
KR102958021B1 (ko) 2019-12-25 2026-04-27 아스테라스 세이야쿠 가부시키가이샤 피리다지닐 티아졸카르복시아미드 화합물
JPWO2022114164A1 (enExample) * 2020-11-30 2022-06-02
WO2022114164A1 (ja) * 2020-11-30 2022-06-02 アステラス製薬株式会社 ヘテロアリールカルボキシアミド化合物
CN116528864A (zh) * 2020-11-30 2023-08-01 安斯泰来制药株式会社 杂芳基甲酰胺化合物
JP7397452B2 (ja) 2020-11-30 2023-12-13 アステラス製薬株式会社 ヘテロアリールカルボキシアミド化合物
US12077519B2 (en) 2020-11-30 2024-09-03 Astellas Pharma Inc. Heteroaryl carboxamide compound

Also Published As

Publication number Publication date
US20140135331A9 (en) 2014-05-15
US8455658B2 (en) 2013-06-04
TW200806643A (en) 2008-02-01
CA2639910A1 (en) 2007-08-02
WO2007087427A3 (en) 2008-02-21
EP1983980A2 (en) 2008-10-29
TWI444370B (zh) 2014-07-11
EP1983980A4 (en) 2010-05-05
WO2007087427A2 (en) 2007-08-02
AU2007208225A1 (en) 2007-08-02
AU2007208225B2 (en) 2013-05-02
US20130317032A1 (en) 2013-11-28
US20070254925A1 (en) 2007-11-01

Similar Documents

Publication Publication Date Title
US8455658B2 (en) Thiazole and thiadiazole compounds for inflammation and immune-related uses
US8710083B2 (en) Pyridylphenyl compounds for inflammation and immune-related uses
AU2007208240B2 (en) Substituted biaryl compounds for inflammation and immune-related uses
JP5184891B2 (ja) 炎症及び免疫に関連する用途に用いる化合物
JP5538894B2 (ja) 炎症及び免疫関連使用のためのシクロヘキセニル−アリール化合物
US8314130B2 (en) Compounds inclunding substituted pyridines for inflammation and immune-related uses
US20100130522A1 (en) Compounds for inflammation and immune-related uses
AU2007208239A1 (en) Substituted aromatic compounds for inflammation and immune-related uses
AU2006208045A1 (en) Compounds for inflammation and immune-related uses
JP2010535214A (ja) 炎症および免疫関連用途のための複素環−アリール化合物
AU2012216699A1 (en) Compounds for inflammation and immune-related uses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120807

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121031

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121203

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130703

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130820

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20130913